Crestor (Rosuvastatin) (Crestor 20 mg) and Darolutamide: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Darolutamide inhibition of BCRP and OATP transporters substantially increases rosuvastatin exposure.
Clinical significance and safety
The EMA product information reports approximately five-fold higher rosuvastatin exposure in the studied combination and recommends avoiding co-administration unless there is no therapeutic alternative. This is relevant to Crestor (Rosuvastatin) with Darolutamide. Report muscle pain, marked weakness or dark urine promptly, and let the treatment team arrange an alternative or monitoring plan.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.